Tanke Biosciences (TNBI) Ratios
Tanke Biosciences Ratios
TNBI's free cash flow for Q2 2025 was $-870.00. For the 2025 fiscal year, TNBI's free cash flow was increased by $0.00 and operating cash flow was $-869.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.00 | 0.02 | 0.08 | 0.41 |
| Quick Ratio | 0.02 | 0.00 | 0.02 | 0.08 | 0.41 |
| Cash Ratio | 0.01 | 0.00 | 0.02 | 0.08 | 0.41 |
| Solvency Ratio | -0.58 | -0.48 | -0.45 | 0.31 | -0.54 |
| Operating Cash Flow Ratio | -0.08 | -0.14 | -0.45 | -0.62 | -0.03 |
| Short-Term Operating Cash Flow Coverage | -0.26 | -0.25 | -0.53 | -1.12 | -1.97 |
| Net Current Asset Value | $ -462.76K | $ -248.86K | $ -162.16K | $ -88.13K | $ -59.98K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.88 | 2.14 | 2.02 | 7.25 | 0.04 |
| Debt-to-Equity Ratio | -0.35 | -0.76 | -1.46 | -0.60 | -0.03 |
| Debt-to-Capital Ratio | -0.54 | -3.23 | 3.16 | -1.51 | -0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.19 | -0.36 | -0.72 | -0.08 | -0.69 |
| Debt Service Coverage Ratio | -1.64 | -0.83 | -0.09 | 0.28 | -14.73 |
| Interest Coverage Ratio | -15.53 | -129.37 | -1.69 | -2.31 | -345.24 |
| Debt to Market Cap | 0.21 | 0.18 | 0.04 | 0.04 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Net Debt to EBITDA | -0.52 | -1.20 | -7.53 | 1.52 | 0.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -3058.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -3040.34% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -3058.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -3255.80% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -3255.80% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -3255.80% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 106.44% | 102.14% | 87.64% | 76.57% | 108.23% |
| Return on Assets (ROA) | -368.55% | -183.04% | -119.33% | -1341.21% | -1742.34% |
| Return on Equity (ROE) | 68.82% | 65.41% | 86.27% | 111.36% | 1205.29% |
| Return on Capital Employed (ROCE) | 64.66% | 64.04% | 98.44% | 145.44% | 1113.68% |
| Return on Invested Capital (ROIC) | 99.64% | 270.92% | -212.34% | 365.11% | 1148.03% |
| Return on Tangible Assets | -543.81% | -288.84% | -182.75% | -1341.21% | -1742.34% |
| Earnings Yield | -40.98% | -15.70% | -2.61% | -7.78% | -4.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.01 | 0.00 | 0.77 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -70917.59 | 0.00 | -472.35 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 70917.59 | 0.00 | 472.35 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -12329.00 | 0.00 | 0.00 | -19725.67 | 0.00 |
| Capital Expenditure Coverage Ratio | -12329.00 | 0.00 | 0.00 | -19725.67 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.26 | -0.25 | -0.53 | -1.12 | -1.97 |
| Operating Cash Flow to Sales Ratio | -4.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -5.52% | -4.57% | -2.36% | -4.69% | -0.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.44 | -6.38 | -38.35 | -12.85 | -21.51 |
| Price-to-Sales (P/S) Ratio | 79.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -1.68 | -4.17 | -33.09 | -14.31 | -259.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.11 | -21.89 | -42.39 | -21.31 | -4405.24 |
| Price-to-Operating Cash Flow Ratio | -18.11 | -21.89 | -42.39 | -21.31 | -4405.24 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | -0.31 | 0.76 | 0.15 | 0.00 |
| Enterprise Value Multiple | -3.14 | -7.76 | -180.93 | 43.53 | -282.25 |
| Enterprise Value | 803.70K | 903.93K | 3.30M | 1.31M | 15.51M |
| EV to EBITDA | -3.14 | -7.76 | -180.93 | 43.53 | -282.25 |
| EV to Sales | 95.34 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -21.73 | -25.90 | -44.23 | -22.09 | -4393.99 |
| EV to Operating Cash Flow | -21.73 | -25.90 | -44.23 | -22.09 | -4393.99 |
| Tangible Book Value Per Share | -0.02 | -0.01 | -0.01 | -0.01 | -0.00 |
| Shareholders’ Equity Per Share | -0.02 | -0.01 | -0.00 | -0.01 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.00 | -0.00 | -0.01 | -0.06 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.06 | 1.02 | 3.08 | 0.77 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 31.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.13 | 0.29 | 0.90 | 0.60 | 0.00 |
Currency in USD
